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prove HRQoL. Factors other than medications adherence should be focused in
further studies to improve HRQoL.
PR2
A FEASIBILITY STUDY OF PREFERENCE-BASED HEALTH-RELATED QUALITY OF
LIFE MEASURES ON PATIENTS WITH IRRITABLE BOWEL SYNDROM IN TAIWAN
Hsu CC1, Chen LC2, Wen YH1, Su YC3
1KaohsiungMedical University, Kaohsiung, Taiwan, 2University of Nottingham, UK,
3KaohsiungMunicipal Ta-Tung Hospital, Kaohsiung, Taiwan
OBJECTIVES: Irritable bowel syndrome (IBS) is a relapsing, chronic functional gas-
trointestinal disorder leading to long-term disturbances on health-related quality
of life (HRQoL). Various functional and QoLmeasures have been developed to eval-
uate IBS outcomes, but none of the preference-based QoL measure has been ap-
plied and validated on Taiwanese people. This study aimed to explore the feasibil-
ity of applying preference-based HRQoL measures to IBS patients in Taiwan.
METHODS: This prospective study was conducted from July to December 2010 at
gastroenterology clinics in a regional hospital in southern Taiwan. IBS outpatients
diagnosed by Rome III criteria were invited into participate semi-structure inter-
view survey by using EuroQol (EQ-5D) questionnaire, 100-mmvisual analogue scale
(EQ-5D VAS) and standard gamble (SG) method. The EQ-5D assessment was trans-
formed into EQ-5D index using Japanese preference weight. Multiple regression
was used to assess factors associated with utilities, e.g. demographic, socioeco-
nomic status and disease severity. RESULTS: Of all, 29 participants (mean age
45.816.5 years; 62.1% female) completed QoL survey, except for one rejected SG
survey for disagreeing with SG hypothesis. Participants’ IBS subtypes include con-
stipation (n11; 37.9%), diarrhea (n16; 55.2%) and unsubtyped IBS (n2; 6.9%);
and 12 (41.4%) participants were newly diagnosed IBS and 12 had over two-year
disease history. Participants had no problem in EQ-5D survey, some expressed
difficulties in dimensions of pain/discomfort and anxiety/depression. Mean utility
derived from SG (0.850.16), EQ-5D index (0.790.15) and EQ-5D VAS (0.590.17)
were significantly different (p0.05). SG utility was significantly associated with
unsubtyped IBS and whether the IBS was newly diagnosed (p0.05).
CONCLUSIONS: IBS is well-tolerated but causing problem in anxiety/depression
and pain/discomfort in QoL survey.Mean utility of SG is higher than results derived
from EQ-5D and EQ VAS, and this finding matches previous literature. Further
validate the utility measures in more IBS patients with various subtypes and se-
verity is needed.
PR3
UTILITY VALUES FOR CHEMOTHERAPY-RELATED ADVERSE EVENTS: A REVIEW
OF THE LITERATURE
Shabaruddin FH1, Chen LC2, Elliott R2, Payne K3
1University of Malaya, Kuala Lumpur, Malaysia, 2University of Nottingham, UK,
3University of Manchester, Manchester, UK
OBJECTIVES: Chemotherapy offers cancer patients the potential benefits of im-
proved mortality and morbidity but may cause detrimental outcomes due to ad-
verse drug events (ADEs) that could require time-consuming, resource-intensive
and costly clinical management. To appropriately assess chemotherapy agents in
an economic evaluation, the impact of ADEs could be included in terms of their
incidence, costs of their management and valuation of the perceived disbenefits
via (dis)utility of ADEs. This review aimed to identify published studies reporting
utility values for chemotherapy-related ADEs. METHODS: A structured electronic
search combining terms for utility, utility valuationmethods and generic terms for
cancer treatment was conducted in MEDLINE and EMBASE in June 2011. Inclusion
criteria were: 1) primary data, and 2) elicitation of utility of chemotherapy-related
ADE. Two reviewers identified studies and extracted data independently. Any dis-
agreements were resolved by a third reviewer. RESULTS: Eighteen studies met the
inclusion criteria from the 853 abstracts initially identified, collectively reporting
218 utility values for chemotherapy-related ADEs. All eighteen studies used short
descriptions (vignettes) to obtain the utility values. Of the 218 utility values, 178
were elicited using SG or TTO while 40 were elicited using VAS. There were 169
utility values of specific chemotherapy-related ADEs (with the top ten being anae-
mia (34 values), nausea and/or vomiting (32 utility values), neuropathy (21 values),
neutropaenia (12 values), diarhoea (12 values), stomatitis (10 values), fatigue (8
values), allopecia (7 values), hand-foot syndrome (5 values) and skin reaction (5
values)) and 49 of non-specific chemotherapy-related adverse events.
CONCLUSIONS: This study has summarised the current evidence base of utility
values for chemotherapy-related ADEs. Only 178 of the 218 values were elicited
using choice-basedmethods (SG & TTO) and therefore could potentially be used as
parameter inputs in an economic evaluation incorporating ADEs of a chemother-
apy agent.
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OBJECTIVES: The current study is to quantify the burden of neuropathic pain (NeP)
with respect to health status, work productivity loss, and health care resource
utilization among patients in Japan. METHODS: The 2010 Japan National Health
andWellness Survey (NHWS), a self-reported, Internet-based survey of adult Japan
population, was used as the data source for this study (N25,000). All respondents
were categorized as those reporting either NeP, a form of pain other than NeP, and
no pain. These groups were compared on health status (using the SF-12v2), work
productivity loss (using the WPAI), and health care resource use (provider visits,
hospitalizations, and emergency room (ER) visits) in the past six months using
regression modeling controlling for demographics, health behaviors, and
comorbidities. RESULTS: Of the 25,000 patients in Japan, 0.23% (n58) reported
experiencing NeP, 5.57% (n1392) reported experiencing another form of pain, and
94.20% reported experiencing no pain in the past month. Adjusting for covariates,
patients experiencing NeP reported significantly worse physical and mental com-
ponent summary scores (42.43 and 41.60, respectively) than patients experiencing
another form of pain (45.41 and 44.83, respectively) and patients without pain
(51.03 and 47.41, respectively) (all p.05). A similar pattern was observed for health
utilities (Nep0.66 vs. Other pain0.69 vs. No pain0.76). Overall work impairment
was similar between those with NeP and those with other pain (36.50% vs. 26.63%,
respectively, p.21); however, patients with NeP reported greater overall work im-
pairment than those without pain (16.50%, p.05). Patients with NeP also reported
significantly more provider visits (18.85) than those with other pain (8.21) and no
pain (4.60) (all p.05). CONCLUSIONS: Patients in Japan with NeP report signifi-
cantly worse humanistic and economic outcomes compared with those without
pain and even other forms of pain. The results suggest improved management of
NeP may have substantial health outcome benefits.
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OBJECTIVES:The incidence of cancer is on rise inMalaysia. Despite the existence of
different screening methods the response to screening is poor. The current study
aims to examine cancer patients’ perceptions towards cancer screening and early
diagnosis. METHODS: A qualitative methodology was used to collect in-depth in-
formation from consented cancer patients, recruited from February to July 2010.
After obtaining institutional ethical approval, patients with different types and
stages of cancer from the three major ethnic groups (Malay, Chinese and Indian)
were approached. Twenty semi-structured interviews were conducted. All inter-
views were audio taped, transcribed verbatim and translated into English for the-
matic content analysis. RESULTS: Thematic content analysis yielded four major
themes: Awareness on cancer screening, perceived benefits of cancer screening,
perceived barriers to cancer screening and cues to action. Majority of the respon-
dents had never heard of cancer screening before the diagnosis. Some accounted of
heedingmammogram and pap-smear tests but did not undergo screening due to a
lack of personal susceptibility. Those who have had negative results of screening
prior to diagnosis perceived such tests as untrustworthy. Lack of knowledge and
financial constrains were reported as barriers to cancer screening. Finally, numer-
ous suggestions were given to improve screening behaviour among healthy indi-
viduals, including role of mass media in disseminating the message ‘prevention is
better than cure’. CONCLUSIONS: Patients’ narratives revealed some significant is-
sues that were in line with the health belief model which could explain negative
health behaviour. The description of the personal experiences with the cancer
could provide many cues to action for those who have never encountered this
potentially deadly disease if incorporated into health promotion activities.
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OBJECTIVES: Rural patients in China requiring cardiac and vascular interventional
treatment typically have to travel to an urban “tier3” hospital for treatment instead
of using their local “tier2” hospital due to lack of equipment. To understand the
economic drivers of improved patient access in China a pilot study was initiated.
METHODS: Data were collected on patient numbers, clinical and social groups,
insurance type, reimbursement rates, and travel costs as well as distance travelled
for a period six months before and after installation of equipment in the tier2
hospital. RESULTS: The hospitals chosen were Fengnan Hospital (tier2) and Gon-
gren Hospital (tier3) in Tangshan City and were only 13KM apart. Tier3 hospital
patients are reimbursed 55%, 65% and 80% for rural patients (43%), urban resident
(29%) and urban workers (18%) respectively. 10% of patients are not covered by
insurance and pay all costs. Tier2 hospital patients are reimbursed 70%, 75% and
85%. In the tier3 hospital during the 6 months before the equipment was installed,
1700 patients were treated at an average cost to the patient of 2905 CNY. In tier 2
hospital in the six months following installation, 107 patients were treated at an
average cost of 1925 CNY/patient, saving 980 CNY direct cost per patient or 34%. In
addition travel costs were reduced by 31 CNY/patient. CONCLUSIONS: The varia-
tion in reimbursement strategy for tier2 and tier3 hospitals offer the best financial
opportunity for improving access to treatment for patients, however further work
is needed to compare regional differences and also the effect of patients having to
travel greater distances.
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